Descemet Endothelial Thickness Comparison Trial II (DETECT II): multicentre, outcome assessor-masked, placebo-controlled trial comparing Descemet membrane endothelial keratoplasty (DMEK) to Descemet stripping only (DSO) with adjunctive ripasudil for Fuchs dystrophy

• Published in: BMJ open ophthalmology 2024-10, Vol.9 (1), p.e001725
• Main Authors: Lin, Charles C, Chamberlain, Winston, Benetz, Beth Ann, Gensheimer, William, Li, Jennifer Y, Jeng, Bennie H, Clover, Jameson, Varnado, Nicole, Abdelrahman, Sarah, Srinivasan, Amrita, Syed, Zeba A, Koo, Ellen H, Arnold, Benjamin F, Lietman, Thomas M, Lass, Jonathan, Rose-Nussbaumer, Jennifer
• Format: Article
• Language: English
• Subjects: Adjuvants; Aged; Cataracts; Cell cycle; clinical trial; Clinical trials; Committees; cornea; Corneal transplantation; Descemet Membrane - surgery; Descemet Stripping Endothelial Keratoplasty - methods; Endothelium; Endothelium, Corneal - pathology; Eye surgery; Female; Fuchs' Endothelial Dystrophy - drug therapy; Fuchs' Endothelial Dystrophy - surgery; Humans; Intraocular lenses; Isoquinolines - administration & dosage; Isoquinolines - therapeutic use; Kinases; Male; Middle Aged; Multicenter Studies as Topic; Ophthalmic Solutions - therapeutic use; Patients; Protocol; Sulfonamides - administration & dosage; Sulfonamides - therapeutic use; Surgeons; Treatment Outcome; Visual acuity; Visual Acuity - drug effects
• ISSN: 2397-3269; 2397-3269
• DOI: 10.1136/bmjophth-2024-001725

IntroductionIt remains uncertain whether Descemet membrane endothelial keratoplasty (DMEK) or Descemet stripping only (DSO) yields better outcomes in patients with symptomatic Fuchs endothelial corneal dystrophy (FECD). This paper presents the protocol for the Descemet Endothelial Thickness Comparison Trial II (DETECT II), a multicentre, outcome-masked, randomised, placebo-controlled, clinical trial comparing DMEK to DSO with ripasudil (DSO-R) for this patient population.Methods and analysisA total of 60 patients with endothelial dysfunction due to symptomatic FECD will be enrolled from seven participating sites in the USA. The patients will be randomly assigned in a 1:1 ratio to one of the following treatment groups: group 1—DMEK plus topical placebo and group 2—DSO plus topical ripasudil 0.4%. The enrolment period is 24 months. The primary outcome is best spectacle-corrected visual acuity at 12 months. Secondary outcomes include peripheral and central endothelial cell density, visual acuity, vision-related quality of life and Pentacam Scheimpflug tomography. Study outcomes will be analysed using mixed effects linear regression. Adverse events, including rebubble procedures, endothelial failure and graft rejection, will be documented and analysed using appropriate statistical methods. DETECT II aims to provide evidence on the comparative effectiveness of DMEK and DSO-R. The results of this trial will contribute to optimising the treatment of FECD, while also exploring the cost-effectiveness of these interventions. Dissemination of findings through peer-reviewed publications and national/international meetings will facilitate knowledge translation and guide clinical practice in the field of corneal transplantation.Ethics and disseminationA data and safety monitoring committee has been empanelled by the National Eye Institute. All study protocols will be subject to review and approval by WCG IRB as the single IRB of record. This study will comply with the National Institute of Health (NIH) Data Sharing Policy and Policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. Data from the trial will be made available on reasonable request.Trial registration numberNCT05275972.